Featured Content

Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations

Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for ...

Opinion: Understanding the FDA's Take on Cannabidiol

In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.

Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing

"People have shown that the variant-identification quality of WGS is superior to WES," said Dr Gerstein.

Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves

Patient-reported outcomes, or PROs, are going to play a larger role in FDA cancer drug approvals, according to an expert in the field.

Reducing the Reliance on Opioids for Cancer Pain: Is the Switch to Cannabis a Viable Option?

Articles discussing the use of cannabis as a substitute for opioids highlight the limitations of the existing scientific evidence in the field.

More Features>>>

Video Series

Multiple Myeloma Resources

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs